Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and oxaliplatin combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma
ChiCTR-TNRC-11001557Phase 4Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gemcitabine, oxaliplatin and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: overall survival. Started Sep 2011; status: completed.
02
Drugs
gemcitabineoxaliplatinsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TNRC-11001557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-11001557.